# Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01529632** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 193 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** QVA149
- **DRUG:** NVA237
- **DRUG:** QAB149
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01529632
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2014-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529632, "Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01529632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*